Incidence of paroxysmal atrial tachycardias in patients treated with cardiac resynchronization therapy and continuously monitored by device diagnostics

Europace

Volumn 12, Issue 1, 2010, Pages 71-77

  Leclercq, C ^a   Padeletti, L ^b   Cihak R ^c   Ritter, P ^d   Milasinovic, G ^e   Gras, D ^f   Paul, V ^g   Van Gelder, I C ^h   Stellbrink, C ⁱ   Rieger, G ^j   Corbucci, G ^j   Albers, B ^j   Daubert, J C ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Institut Klinické A Experimentální   (Czech Republic)

^d Centre Chirurgical Val d'Or   (France)

^e CLINICAL CENTER OF SERBIA   (Serbia)

^f Nouvelles Cliniques Nantaises   (France)

^g ST PETER S HOSPITAL   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^j Medtronic SQDM   (Netherlands)

more..

Author keywords

Atrial fibrillation; Biventricular pacing; CRT; Heart failure; Pacemaker; Paroxysmal atrial tachycardia

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; WARFARIN;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CONGESTIVE HEART FAILURE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; IMPLANTATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONITORING; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; QRS COMPLEX; TELEMETRY;

EID: 73849119887     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup318     Document Type: Article

References (36)

1. Maisel WH, Stevenson LW. a trial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D-8D.
2. Ehrlich JR, Nattel S, Hohnloser SH. a trial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol 2002;13:399-405.
3. Patten M, Maas R, Bauer P, Lüderitz B, Sonntag F, Dluzniewski M et al. Suppression of paroxysmal a trial tachyarrhythmias-results of the SOPAT trial. Eur Heart J 2004;25:1395-1404
4. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T et al. The Prevention of a trial Fibrillation after Cardioversion Investigators. Prevention of a trial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004;25:1385-1394
5. Patten M, Maas R, Karim A, Müller HW, Simonovsky R, Meinertz T. Eventrecorder monitoring in the diagnosis of a trial fibrillation in symptomatic patients: subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol 2006;17:1-5.
6. Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R et al. Asymptomatic a trial fibrillation: demographic features and prognostic information from the a trial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:657-663
7. Sulfi S, Balami D, Sekhri N, Suliman A, Kapur A, Archbold RA et al. Limited clinical utility of Holter monitoring in patients with palpitations or altered consciousness: analysis of 8973 recordings in 7394 patients. Ann Noninvasive Electrocardiol 2008; 13:39-43.
8. Senatore G, Stabile G, Bertaglia E, Donnici G, De Simone A, Zoppo F et al. Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with a trial fibrillation. J Am Coll Cardiol 2005;45:873-876
9. Kottkamp H, Tanner H, Kobza R, Schirdewahn P, Dorszewski A, Gerds-Li JH et al. Time courses and quantitative analysis of a trial fibrillation episode number and duration after circular plus linear left a trial lesions. J Am Coll Cardiol 2004;44: 869-877
10. Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of a trial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004;35:1647-1651
11. Nash A, Frö hlig G, Taborsky M, Stammwitz E, Maru F, Bouwens LH et al. Rejection of a trial sensing artifacts by a pacing lead with short tip-to-ring spacing. Europace 2005;7:67-72.
12. American Society of Echocardiography, Committee on Standards. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:338-367
13. Boriani G, Bertaglia E, Carboni A, Latini R, Biffi M, Martignani C et al. A controlled study on the effect of verapamil on a trial tachyarrhythmias in patients with bradytachy syndrome implanted with a DDDR pacemaker. Int J Cardiol 2005;104:73-76
14. Pérez FJ, Lung TH, Ellenbogen KA, Wood MA. Is time to first recurrence of a trial fibrillation correlated with a trial fibrillation burden? Am J Cardiol 2006;97:1343-1345
15. Lewalter T, Yang A, Pfeiffer D, Ruiter J, Schnitzler G, Markert T et al. Individualized selection of pacing algorithms for the prevention of recurrent a trial fibrillation: results from the VIP registry. Pacing Clin Electrophysiol 2006;29:124-134
16. Camm AJ, Sulke N, Edvardsson N, Ritter P, Albers BA, Ruiter JH, on behalf of the AFTherapy Investigators. Conventional and dedicated a trial overdrive pacing for the prevention of paroxysmal a trial fibrillation: the AFTherapy study. Europace 2007;9:1110-1118
17. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJV et al. on behalf of the CHARM Investigators. a trial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) Program. J Am Coll Cardiol 2006;47:1997-2004.
18. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP et al. on behalf of the CHARM Investigators. Prevention of a trial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;152:86-92.
19. Tse HF, Lau CP. Prevalence and clinical implications of a trial fibrillation episodes detected by pacemaker in patients with sick sinus syndrome. Heart 2005;91: 362-364
20. Sulke N, Silberbauer J, Boodhoo L, Freemantle N, Kamalvand K, O'Nunain S et al. The use of a trial overdrive and ventricular rate stabilization pacing algorithms for the prevention and treatment of paroxysmal a trial fibrillation: the Pacemaker a trial Fibrillation Suppression (PAFS) study. Europace 2007;9:790-797
21. Kiès P, Leclercq C, Bleeker GB, Crocq C, Molhoek SG, Poulain C et al. Cardiac resynchronisation therapy in chronic a trial fibrillation: impact on left a trial size and reversal to sinus rhythm. Heart 2006;92:490-494
22. Brignole M, Gammage M, Puggioni E, Alboni P, Raviele A, Sutton R et al. Comparative assessment of right, left, and biventricular pacing in patients with permanent a trial fibrillation. Eur Heart J 2005;26:712-722
23. Garrigue S, Bordachar P, Reuter S, Jaïs P, Kobeissi A, Gaggini G et al. Comparison of permanent left ventricular and biventricular pacing in patients with heart failure and chronic a trial fibrillation: prospective haemodynamic study. Heart 2002;87: 529-534
24. Leclercq C, Victor F, Alonso C, Pavin D, Revault d'Allones G, Bansard JY et al. Comparative effects of permanent biventricular pacing for refractory heart failure in patients with stable sinus rhythm or chronic a trial fibrillation. Am J Cardiol 2000;85:1154-1156
25. Leclercq C, Walker S, Linde C, Clementy J, Marshall AJ, Ritter P et al. on behalf of the MUSTIC Study Group. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic a trial fibrillation. Eur Heart J 2002;23:1780-1787 (Pubitemid 35334271)
26. Gasparini M, Auricchio A, Regoli F, Fantoni C, Kawabata M, Galimberti P et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression. The importance of performing atrioventricular junction ablation in patients with a trial fibrillation. J Am Coll Cardiol 2006;48:734-743
27. Puglisi A, Gasparini M, Lunati M, Sassara M, Padeletti L, Landolina M et al. on behalf of InSync III Italian Registry Investigators. Persistent a trial fibrillation worsens heart rate variability, activity and heart rate, as shown by a continuous monitoring by implantable biventricular pacemakers in heart failure patients. J Cardiovasc Electrophysiol 2008;19:693-701.
28. Hoppe UC, Casares JM, Eiskjær H, Hagemann A, Cleland JG, Freemantle N et al. Effect of cardiac resynchronization on the incidence of a trial fibrillation in patients with severe heart failure. Circulation 2006;114:18-25.
29. Padeletti L, Muto C, Maounis T, Schuchert A, Bongiorni MG, Frank R et al. for the MASCOT Study Group. a trial fibrillation in recipients of cardiac resynchronization therapy device: 1-year results of the randomized MASCOT trial. Am Heart J 2008;156:520-526.
30. Monte S, Macchia A, Pellegrini F, Romero M, Lepore V, D'Ettorre A et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with a trial fibrillation. Eur Heart J 2006;27:2217-2223
31. Rowan SB, Bailey DN, Bublitz CE, Anderson RJ. Trends in anticoagulation for a trial fibrillation in the U.S. an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol 2007;49:1561-1565
32. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH et al. on behalf of the Euro Heart Survey Investigators. Antithrombotic treatment in real-life a trial fibrillation patients: a report from the Euro Heart Survey on a trial Fibrillation. Eur Heart J 2006;27:3018-3026
33. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with a trial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With a trial Fibrillation). Circulation 2006;114: e257-e354.
34. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R et al. a trial high rate episodes detected by pacemaker diagnostics predict death and stroke. Report of the a trial diagnostics ancillary study of the MOde Selection Trial (MOST). Circulation 2003;107:1614-1619
35. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G et al. Monitored a trial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and a trial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005;46:1913-1920
36. Hügl B, Bruns HJ, Unterberg-Buchwald C, Grosse A, Stegemann B, Lauer B et al. a trial fibrillation burden during the post-implant period after CRT using devicebased diagnostics. J Cardiovasc Electrophysiol 2006;17:813-817